Analia Carmo

Abstract : The use of antifungal drugs started in the 1950s with polyenes nystatin, natamycin and amphotericin B-deoxycholate (AmB). Until the present day, AmB has been considered to be a hallmark in the treatment of invasive systemic fungal infections. Nevertheless, the success and the use of AmB were associated with severe adverse effects which stimulated the development of new antifungal drugs such as azoles, pyrimidine antimetabolite, mitotic inhibitors, allylamines and echinochandins.

SHORT COMMUNICATION Anália Carmo Corresponding Author E-mail address: 10919@chuc.min-saude.pt http://orcid.org/0000-0002-7704-4736 Laboratory of Molecular Biology/Virology, Clinical Pathology Unit, Centro Hospitalar e Universitário de Coimbra, Portugal Correspondence Anália Carmo, Laboratory of Molecular Biology/Virology, Clinical Pathology Unit, Centro Hospitalar e Universitário de Coimbra, Portugal.

Novel treatment (new drug/intervention; established drug/procedure in new situation) Posaconazole in the treatment of refractory Purpureocillium lilacinum (former Paecilomyces lilacinus) keratitis: the salvation when nothing works Mariana Almeida Oliveira1, Analia Carmo2, Andreia Rosa1,3 and Joaquim Murta1,3 1 Department of Ophthalmology, Centro Hospitalar e Universitario de Coimbra EPE, Coimbra, Portugal 2 Clinical Pathology, Centro Hospitalar e Universitario de Coimbra EPE, Coimbra,...